FOR IMMEDIATE RELEASE:
PrimeraDx Appoints George N. Serbedzija as Vice President of Business Development
Mansfield, MA — July 14, 2008 — PrimeraDx today announced that George N. Serbedzija, Ph.D. has joined the company as Vice President of Business Development effective immediately.
“We are very pleased with the appointment of Dr. Serbedzija because he brings a broad range of experience from the biotechnology and diagnostics industries. His appointment builds upon our existing management and development strengths as we continue to advance our multiplexed, quantitative assays and platform to market, "said Martin L. Verhoef, President and CEO of PrimeraDx.
"I am excited to join the management team during this important stage of the Company's development and look forward to contributing to the future success of PrimeraDx," commented Dr. Serbedzija.
Dr. Serbedzija most recently served as Director of Business Development for Genzyme Genetics, a national reference laboratory focused on Oncology and Reproductive diagnostic testing and screening. Prior to Genzyme Genetics, he held various management positions at CombinatoRx, Inc, first as head of the Infectious Disease program and then as Associate Director of Corporate Development.
Dr. Serbedzija began his commercial career as a founding member of Phylonix, a Contract Research Organization providing in vivo assays for drug discovery and screening. He received his PhD in Developmental Neurobiology at the University of California, Irvine and a B.S. in Zoology at the University of California, Davis.
PrimeraDx is dedicated to the emerging field of molecular diagnostics. The company is developing multiplexed, quantitative and cost effective assays using its proprietary STAR technology implemented on the ICEPlex instrument platform. STAR combines quantitative PCR with the ability to multiplex up to 60 targets in a single sample. The Company’s initial products are for infectious disease management. PrimeraDx plans to extend its focus into oncology to support cancer therapy management through diagnostic, prognostic, staging and therapeutic monitoring. The Company’s website is: www.primeradx.com .